REGENXBIO Inc. (RGNX)
Nasdaq · Healthcare · Biotechnology
$7.76+4.44%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $512M
- 52-week range
- $5.46 – $16.19
- 52-week change
- −29.31%
- EPS (trailing)
- −$3.78
- Analyst rating
- 1.6 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $170M (+104.54%)
- Net income
- −$194M
- Operating margin
- −94.6%
- Diluted EPS
- −$3.76
- Free cash flow
- −$126M
From the company’s annual report on SEC EDGAR.
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Headquarters: Rockville, United States · 371 employees · regenxbio.com